Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:PETS News 12 December 2025

PetMed Express (PETS) Stock: $4 Takeover Proposal Sparks Surge — News, Forecasts, and Key Risks on Dec. 12, 2025

PetMed Express (PETS) Stock: $4 Takeover Proposal Sparks Surge — News, Forecasts, and Key Risks on Dec. 12, 2025

Updated: Friday, December 12, 2025 (US market context). PetMed Express, Inc. (NASDAQ: PETS ) — best known as PetMeds and the parent of PetCareRx — is back on traders’ radars after a Singapore-based investor publicly disclosed an unsolicited proposal to take the online pet pharmacy private at $4.00 per share in cash . The news sent PETS sharply higher on Thursday, and the market is now trying to answer one question: Is the bid real enough to anchor the stock near $4, or is this a volatility event with meaningful execution risk? GlobeNewswire+ 2DRY+ 2 Below is a comprehensive roundup
12 December 2025
··

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
Go toTop